Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority Pharmaceutical TechnologyMSD and Daiichi Sankyo have received priority review from the FDA for ifinatamab deruxtecan's BLA to treat ES-SCLC.RegulatoryOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaceutical Technology MSD and Daiichi Sankyo have received priority review from the FDA for ifinatamab deruxtecan’s BLA to treat ES-SCLC. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Alamar, Hemab, Kailera, and Seaport advance IPOsNext: Revolution rockets on strong pancreatic cancer data Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
